Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1683307

registered interest
date	18/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 December 2023 to Question 5383 on NHS: Standards, what steps her Department is taking to to ensure quality improvement across (a) NHS England, (b) Integrated Health and Care Boards and (c) NHS Hospital Trusts.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	10452
answer	answer is ministerial correction date of answer 23/01/2024 answer text <p>NHS Improving Patient Care Together is the single improvement approach to support all National Health Service organisations, systems, and providers at every level, including NHS England, to have the skills and techniques to deliver continuous improvement. Information and resources are available at the following link:</p><p> </p><p><a href="https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.england.nhs.uk%2Fnhsimpact%2Fabout-nhs-impact%2F&amp;data=05%7C02%7CFrancesca.Day%40dhsc.gov.uk%7C679a326c09594acdc07e08dbfc005597%7C61278c3091a84c318c1fef4de8973a1c%7C1%7C0%7C638380850600125951%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=3fC5Kj0WuJz7kdclLWI9HRzV20VSjoxtP%2BMzeb3RHbk%3D&amp;reserved=0" target="_blank">https://www.england.nhs.uk/nhsimpact/about-nhs-impact/</a></p><p> </p><p>The performance of integrated care boards (ICBs) in the exercise of their functions is assessed, annually, by NHS England. The NHS Oversight Framework describes NHS England’s approach to the oversight of ICBs, and is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/nhs-oversight-framework/" target="_blank">https://www.england.nhs.uk/nhs-oversight-framework/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/01/2024 09:17:35 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4124 label Biography information for Chi Onwurah

1682875

registered interest
date	17/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cystic Fibrosis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether NICE’s assessment of the costs and benefits of funding a medication takes into account the size of the community affected; and what discussions NICE has had with patients on the use of Kaftrio for the treatment of cystic fibrosis.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	10116
answer	answer is ministerial correction date of answer 23/01/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) does not take the size of the affected community into account when making recommendation on the clinical and cost effectiveness of medicines.</p><p>In 2017, a Budget Impact Test was introduced to mitigate the affordability challenge that higher cost medicines for large patient populations can present to the National Health Service, even at a cost-effective price. If the estimated budget impact of a medicine exceeds £20 million in any of the first three years of its use, NHS England may engage in commercial discussions with the company to mitigate the impact that funding the medicine would have on the rest of the NHS.</p><p>NICE is currently developing guidance for the NHS on the clinical and cost effectiveness of Kaftrio and other cystic fibrosis medicines and is engaging with patient groups as part of the appraisal process. NICE recently consulted on its draft recommendations and is now engaging with key stakeholders to determine the most appropriate next steps. This includes exploring potential commercial solutions.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/01/2024 14:50:02 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4124 label Biography information for Chi Onwurah

1683035

registered interest
date	17/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicine: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to support the research and development of medical technologies in the UK.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	10125
answer	answer is ministerial correction date of answer 23/01/2024 answer text <p>The Department-funded National Institute for Health and Care Research (NIHR) funds research to develop medical technologies through its research programmes, primarily the invention for innovation programme. This programme provides funding to industry and researchers to develop innovative healthcare technologies, including medical devices, which address existing or emerging health and social care needs. The NIHR also supports the development of medical technologies through its research infrastructure, primarily the Medtech and In Vitro Diagnostic Co-operatives, which will be replaced with the NIHR HealthTech Research Centres (HRCs) from 1 April 2024. The 14 NIHR HRCs will work with industry and researchers to support the whole pathway from development of medical devices, diagnostics and digital technologies, through to adoption in the health and care system.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/01/2024 14:44:35 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4124 label Biography information for Chi Onwurah